RxDoctor Payments Data

Maya Carter, MD

Neurology · Annapolis, MDNPI 1437294113

Payments from drug & device makers

$29,006in general payments, 2019–2025

Across 1,493 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Biogen$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • UCB, Inc.$1K
  • Pfizer$1K
  • Amgen$1K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$4502%
  • Speaking & faculty fees$1060%
  • Travel & lodging$2171%
  • Food & beverage$28,04697%
  • Education$1861%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)263$3,529
Biogen122$2,720
Teva Pharmaceuticals USA, Inc.64$1,553
UCB, Inc.64$1,479
Pfizer73$1,457
Amgen(2 entities)69$1,353
Novartis95$1,326
Lilly USA, LLC73$1,251
CSL Behring40$853
Genentech USA, Inc.36$832
Amneal Pharmaceuticals LLC35$704
Lundbeck LLC28$594
Eisai Inc.27$593
Neurocrine Biosciences, Inc.28$583
Sunovion Pharmaceuticals Inc.35$573
Livanova USA, Inc.4$556
Argenx US, Inc.17$460
Neurelis, Inc.22$407
Acadia Pharmaceuticals Inc20$401
Sanofi22$386
Bristol Myers Squibb18$344
Kyowa Kirin, Inc.16$338
Alnylam Pharmaceuticals Inc.12$302
Johnson & Johnson13$285
Grifols USA, LLC13$274
Biohaven Pharmaceuticals, Inc.17$273
Takeda Pharmaceuticals U.S.A., Inc.9$272
AstraZeneca(2 entities)11$264
EMD Serono, Inc.12$257
Sumitomo Pharma America, Inc.12$255
Merz Pharmaceuticals, LLC8$245
Biohaven Pharmaceutical Holding Company Ltd.19$243
Octapharma USA, Inc.11$241
Banner Life Sciences, LLC11$228
Adamas Pharmaceuticals, Inc.17$220
Tanabe Pharma America, Inc.10$218
Greenwich Biosciences, Inc.14$216
Medtronic(2 entities)3$213
Acorda Therapeutics, Inc10$198
Catalyst Pharmaceuticals, Inc.8$192
SK Life Science, Inc.7$190
Upsher-smith Laboratories LLC8$167
Ipsen Biopharmaceuticals, Inc8$142
Avanir Pharmaceuticals, Inc.8$132
MDD US Operations, LLC7$120
E.r. Squibb & Sons, L.L.C.6$111
Vanda Pharmaceuticals Inc.5$110
Axsome Therapeutics, Inc.4$107
Merz North America, Inc.3$93
Supernus Pharmaceuticals, Inc.7$88
Xeris Pharmaceuticals, Inc.4$77
Scilex Pharmaceuticals Inc.4$76
Insightec,inc2$72
Akcea Therapeutics, Inc.1$72
GE HealthCare2$70
Sanofi-aventis U.S. LLC3$69
Mallinckrodt Enterprises LLC2$61
Aquestive Therapeutics, Inc.3$58
Otsuka America Pharmaceutical, Inc.2$48
Almatica Pharma LLC2$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,006 in reported general payments places this provider in the 75th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$826,281
Medicare patients
359
Services billed
19,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lacosamide124$32,922
FycompaPerampanel16$27,433
Clobazam28$19,702
Aimovig AutoinjectorErenumab-Aooe17$19,385
Levetiracetam223$10,895
TegretolCarbamazepine12$8,164
Gabapentin124$4,209
Topiramate ErTopiramate11$4,027
Dalfampridine ErDalfampridine12$3,427
Carbamazepine ErCarbamazepine15$1,790
Escitalopram Oxalate27$1,284
Lamotrigine53$1,259
Topiramate39$1,227
Divalproex Sodium ErDivalproex Sodium14$1,098
Memantine Hcl34$824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$593$27,43316 claims
Upsher-smith Laboratories LLCTopiramate$167$1,22739 claims
Almatica Pharma LLCSertraline Hcl$47$28621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 442 neurology providers in Maryland.

Other neurology in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →